£2 Billion Returns to the UK: What the ABPI’s Competitiveness Report Means for Investment Decisions  9 Sep 2026

A new report from the ABPI, UK Pharmaceutical Investment Competitiveness Report 2026, concludes that the UK has reversed a long-term decline in pharmaceutical investment. Since September 2025, £2 billion of new investment has been committed to the country, spanning AI-enabled drug discovery through to large-scale manufacturing. 

For a sector that has spent several years describing the UK’s position in terms of disinvestment, this is a material change in direction. The report is careful about what it does and does not claim, and the distinction matters: the trend has reversed, but the position has not yet been secured. 

What has changed 

The report identifies four specific policy and system movements behind the shift: 

• The NICE cost-effectiveness threshold has increased for the first time since the early 2000s, to £25,000–£35,000 per QALY. The report attributes nine additional medicines reaching patients to this change. 

• Clawback rates are falling — from 22.9% in 2025 to 14.5% in 2026, on a trajectory towards internationally competitive levels by 2029. 

• MHRA approval times have shortened from 427 days in 2024 to 378 days in 2025, placing the UK fourth fastest globally. 

• The Health Data Research Service is live with £600 million of investment behind it, which the report characterises as a distinct competitive advantage rather than an incremental improvement. 

Taken together, these address both sides of a problem the sector has long described as two separate ones. Approval speed and access conditions have moved in the same direction at the same time, which has not often been the case. 

Where the UK remains strong 

The report ranks the UK in the global top three for seven of nine science base metrics, with 16 of the world’s top 100 universities, world-leading intellectual property protections and a strong talent pipeline. These are long-horizon assets: the report’s own framing is that they took decades to build and could be lost in years. 

The comparison that should concentrate minds 

The most useful figure in the report is not one of the improvements. It is a comparison. On R&D tax credits, Ireland offers 35% and Japan 40%. The UK offers 20%. 

This is worth dwelling on, because it is the kind of benchmarking the sector does too rarely. It is straightforward to demonstrate that the UK has improved against its own recent past — every metric above does exactly that. It is a harder and more useful exercise to establish where the UK sits against the markets it actually competes with for investment, trial placement and launch sequence. On R&D credits, that comparison is unflattering, and the report says so plainly. 

What is at stake 

The report quantifies the opportunity if delivery is sustained: 81,300 new jobs by 2035, taking the sector workforce to 200,000, and annual GVA rising from £20.4 billion to £33.4 billion, alongside faster access to medicines for NHS patients. 

The condition attached to all of it is delivery. Investors commit capital on decade-long horizons, and the report is explicit that confidence remains fragile and contingent on commitments being met consistently rather than announced. 

Our view 

This report speaks directly to a question we put to senior pharmaceutical and biotechnology leaders at our executive forum in July: in five years’ time, will organisations and investors still prioritise the UK? 

The prevailing view in that room was cautious, and for a specific reason. Delegates were near-unanimous that the science base is world-class and that the regulator had become genuinely faster and more willing to engage. They were far less confident that the wider system — assessment, reimbursement, NHS adoption — was moving at a comparable pace. A product could be approved quickly and still wait a long time to reach patients, and it is the second timeline that gets modelled when launch sequence is decided. 

The evidence in this report addresses that concern more directly than anything we have seen in the past two years. A NICE threshold increase and a falling clawback rate are access measures, not approval measures. That is the part of the system delegates identified as the constraint, and it has moved. 

What the report does not settle is whether the movement holds. A threshold that has risen once can stay where it is for another twenty years. A clawback rate on a downward trajectory to 2029 is a trajectory, not an outcome. For any organisation currently deciding where to place a trial or sequence a launch, the practical question is not whether the UK has improved — the report establishes that it has — but whether the improvement is durable enough to plan against. 

On present evidence, the honest answer is that it is too early to know, and that the sector’s own consistency in holding commitments to account will be part of what determines it. 

The full report is available from the ABPI: UK Pharmaceutical Investment Competitiveness Report 2026 

If you are assessing the UK as a market for a trial, a launch or a first European entry, PharmaMedic Consultancy has regulatory and market access experts who can help you work through what these changes mean for your programme. Please contact us for an initial discussion at hello@pharmamedic.co.